Back to Journals » Therapeutics and Clinical Risk Management » Volume 11

Management of bipolar I depression: clinical utility of lurasidone

Authors Findlay LJ, El-Mallakh PL, El-Mallakh R

Received 10 July 2014

Accepted for publication 20 August 2014

Published 8 January 2015 Volume 2015:11 Pages 75—81

DOI https://doi.org/10.2147/TCRM.S57695

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh


Lillian Jan Findlay,1 Peggy El-Mallakh,1 Rif S El-Mallakh2

1College of Nursing, University of Kentucky, Lexington, KY, USA; 2Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USA


Abstract: Lurasidone is a benzisothiazol derivative second-generation antipsychotic. It has been approved in the United States and Europe for treatment of acute schizophrenia and bipolar depression. In type I bipolar subjects, treatment with lurasidone monotherapy of adjunctive therapy to lithium or valproic acid with doses of 20 to 120 mg once daily with food, results in statistically and clinically significant reduction of depressive symptoms. Patients experience relatively few side effects, which include somnolence, akathisia, nausea, and other gastrointestinal upset. Dopamine related side effects, such as Parkinsonism and elevated prolactin, are rare and mild. Longer term safety data obtained in 6 months long, open continuation observation periods, suggest that metabolic related elevations in weight, glucose, and lipids are absent or minimal. The mechanism of action of lurasidone is not known, but the data are compatible with antagonism of the serotonin 7 receptor. Lurasidone is a new option for the treatment of bipolar depression with relatively few side effects.

Keywords: lurasidone, bipolar disorder, bipolar depression, adjunctive therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]